title: Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
abstract: The authors sought to determine whether nebivolol treatment results in changes in blood pressure (BP), nitric oxide bioavailability, and vascular function in obese African Americans with recently diagnosed stage 1 hypertension. Forty-three obese, hypertensive African Americans (mean BP: systolic, 148.8+/-14.3 mm Hg; diastolic, 90.4+/-8.2 mm Hg) were treated with nebivolol (5-10 mg/d) for 8 weeks. Primary outcomes were change in systolic and diastolic BP and efficacy in reaching normotensive BP. Mean systolic BP decreased by 9.2+/-14 mm Hg (P<.005) and diastolic BP decreased 6.8+/-9 mm Hg (P<.005) with 8 weeks of therapy. Significant improvements were seen in arterial compliance with nebivolol treatment as measured by aortic augmentation index (P<.005) and time to wave reflection (P=.013). Nebivolol treatment improved endothelial function as measured by flow-mediated dilation (P<.005). Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<.005). Monotherapy with nebivolol in obese, hypertensive African Americans results in significant systolic and diastolic BP reduction by mechanisms that include improved vascular function and compliance.
authors.affiliation: Department of Cardiology, Emory University, 69 Jesse Hill Drive SE, Atlanta, GA30303, USA.
authors.forename: Nadya
authors.initials: N
authors.lastname: Merchant
authors.forename: Charles D
authors.initials: CD
authors.lastname: Searles
authors.forename: Anbu
authors.initials: A
authors.lastname: Pandian
authors.forename: Syed T
authors.initials: ST
authors.lastname: Rahman
authors.forename: Keith C
authors.initials: KC
authors.lastname: Ferdinand
authors.forename: Guillermo E
authors.initials: GE
authors.lastname: Umpierrez
authors.forename: Bobby V
authors.initials: BV
authors.lastname: Khan
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D001741:Black or African American / Q000706:statistics & numerical data*; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D001578:Benzopyrans / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003187:Compliance / Q000187:drug effects; D003971:Diastole / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D009569:Nitric Oxide; D009765:Obesity / Q000150:complications*; D011446:Prospective Studies; D012039:Regional Blood Flow / Q000187:drug effects; D018570:Risk Assessment; D012307:Risk Factors; D013599:Systole / Q000187:drug effects; D014481:United States / Q000453:epidemiology; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol; D009569:Nitric Oxide; D001262:Atenolol